Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Parkinson's Disease (Jul 2019)

Posted by Matt Breese on Jul 26, 2019

Find me on:

According to our recent payer coverage analysis for Parkinson's disease treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for Parkinson's disease treatments shows that under the pharmacy benefit, about 45% of the lives under commercial formularies are covered without utilization management restrictions.

MMIT-Reality Check-Parkinsons Disease_2Q2019-finalData snapshot as of Q2 2019

Trends: Given the number of generic orals, management of the remaining name-brand oral products is restrictive but less so than in other classes. With many strong orals available, understanding how restrictions translate (or don't) to brand-name products is critical.    

To read the full Reality Check on Parkinson's Disease treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing